Economic Environment - Economic uncertainty is currently heightened due to tariffs and associated price increases, potential inflation, prolonged job searches, and stock market volatility [1] Investment Focus - The primary interest remains in stocks, mutual funds, and ETFs for intermediate- to long-term investing and retirement purposes [1] - The individual has engaged in various investment vehicles including stocks, options, mutual funds, bonds, ETFs, commodities, futures, and forex since 2007 [1] Research and Writing - A strong interest in investment research and analysis has led to a career in freelance financial writing since 2010 [1] - Articles have been published on notable financial websites such as Investopedia, Google Finance, Yahoo Finance, and CBS MoneyWatch, among others [1]

Core Insights - Altria Group and Philip Morris International both produce and sell Marlboro cigarettes, but they operate in different markets, with Altria focusing on North America and Philip Morris on international markets [1][6][7] Company Performance - Altria's cigarette volumes fell by 10.2% in 2024, continuing a negative trend, while Philip Morris saw a 0.6% increase in cigarette volumes in 2025, indicating a more favorable business performance for Philip Morris [8] - Altria has made several strategic mistakes, including the spin-off of Philip Morris, which is now seen as a loss of its best business segment [9][11] Market Positioning - Tobacco companies are classified as consumer staples, but unlike necessities, tobacco products are based on personal preference, leading to scrutiny over health impacts [3][5] - Philip Morris has successfully shifted nearly 39% of its revenue and almost 40% of its gross profit to smoke-free products, positioning itself better for future growth compared to Altria, which still relies on cigarettes for nearly 90% of its revenue [11][12] Investment Considerations - Altria offers a high dividend yield of 6.9%, appealing to income investors, while Philip Morris has a lower yield of 3.1% but is considered a better long-term investment due to its stronger business performance [10][13][14] - For investors with a long-term perspective, Philip Morris is viewed as the more attractive option due to its better positioning and growth potential [14]

Billionaire Ray Dalio is one of the most respected investors out there. Bridgewater Associates, the hedge fund he founded, is generally considered to be the largest hedge fund in the world, with assets under management topping out at $168 billion in 2022. The 75-year-old is known for his "all-weather" portfolio, including gold, balancing risks across asset classes to build a portfolio that can perform well in virtually any economic scenario. He pays close attention to the macro environment, and after a care ...

Core Viewpoint - Philip Morris International has experienced significant stock price appreciation, with shares up nearly 40% in 2025 and over 75% in the past year, following strong earnings results [1][2] Group 1: Earnings Performance - In Q1, Zyn, a nicotine pouch product, saw U.S. shipment volumes increase by 53% to 202 million cans, with international volumes also rising 53% [4][3] - Overall oral product shipments grew by 27%, while traditional cigarette volumes rose by 1.1% to 144.8 billion units [8][7] - Organic revenue increased by 10% year over year to $9.3 billion, with adjusted earnings per share climbing 17% to $1.76 [8][9] Group 2: Growth Drivers - Zyn and heated tobacco units (HTUs), including the IQOS system, are key growth drivers, with HTUs volumes increasing nearly 12% to 37.1 billion units [7][6] - The company expects U.S. Zyn shipments to reach between 800 million and 840 million cans, up from a previous forecast of 780 million to 820 million cans [5][4] - The smoke-free business saw organic revenue surge by 20%, indicating strong demand for non-combustible products [9][10] Group 3: Future Outlook - Philip Morris has maintained its full-year outlook, with organic revenue growth projected between 6% to 8% and adjusted EPS expected to be between $7.01 and $7.14 [11][12] - The company is expanding its capacity in the U.S. for Zyn and testing IQOS in new markets, indicating ongoing growth opportunities [14][13] - The stock is considered undervalued with a forward P/E ratio of 23 and a PEG ratio under 0.4, suggesting potential for further appreciation [15][16]

Core Insights - The article highlights the performance of dividend-paying stocks during market downturns, emphasizing their stability and ability to outperform the S&P 500 in 2025 [1][2] Group 1: AT&T - AT&T is a major U.S. telecom provider with 72.7 million post-paid phone subscribers and 9.3 million fiber optic broadband customers as of the end of 2024 [3] - The stock has a low beta of 0.42, indicating less volatility during market downturns, and offers a dividend yield of 4.1%, which is sustainable as it represents only half of the company's earnings-per-share estimate for 2025 [4] Group 2: Philip Morris International - Philip Morris is the largest tobacco company globally, selling products in 180 countries, and has a beta of 0.44, making it a reliable investment during economic downturns [5] - The company has consistently paid and raised its dividend since 2008, currently yielding 3.2%, and smoke-free products now account for 40% of total sales, indicating a shift towards long-term growth [6] Group 3: The Coca-Cola Company - Coca-Cola is a well-established blue-chip dividend stock with a diverse portfolio of beverages and a low beta of 0.45, making it a stable investment choice [7][8] - The company has a dividend yield of 2.8% and a payout ratio of 69% of 2025 earnings estimates, with a strong track record of increasing dividends over six decades [9]

Core Viewpoint - Altria remains an attractive investment for income investors due to its long history of dividend increases and its current high dividend yield of 7% [1][14] Company Strategy - Altria has faced challenges over the past decade due to declining smoking rates and strategic missteps, including a $12 billion investment in Juul and a failed investment in Cronos Group [5] - The company has shifted focus to smoke-free products, selling the rights to market Iqos back to Philip Morris International and investing in Njoy, which has received FDA marketing authorization for its pod-based e-vapor product [6][8] - Altria's next-gen portfolio includes on!, an oral nicotine pouch, and a new heated tobacco product called Ploom, developed in partnership with JT Group [7] Market Performance - Njoy's consumables saw a 15.3% increase to 12.8 million units, and device shipments rose 22.2% to 1.1 million, with retail market share nearly doubling to 6.4% [8] - Despite Njoy's growth, cigarettes still account for the majority of Altria's revenue, with volume sales declining from 76.4 million in 2023 to 68.6 million in 2024, while smokeable products represented 88% of revenue in 2024 [9] Future Goals - Altria aims for a mid-single digits adjusted earnings per share (EPS) compound annual growth rate (CAGR) off $4.84 in 2022, with adjusted EPS rising 3.4% to $5.12 in 2024, resulting in a 2.9% CAGR over the last two years [10] - The company plans to increase its dividend by mid-single digits annually, following a 4.1% increase in 2024, and targets a debt-to-EBITDA ratio of 2, currently at 2.1 [11] - Altria expects to maintain an adjusted operating margin of at least 60% through 2028, although it has struggled to meet growth targets and has adjusted its expectations for Njoy's cash flow contributions [12] Investment Outlook - Altria's stock trades at a price-to-earnings ratio of 12, with a 7% dividend yield, indicating potential for success even if not all 2028 goals are met [13] - In the current economic climate, Altria is positioned to potentially outperform the S&P 500, benefiting from its status in the consumer staples sector and the consistent demand for its products [14] - Overall, despite declining cigarette consumption, Altria is expected to be in a better position three years from now [15]

The fight for the US nicotine market is heating up. Incumbent MO has been stumbling on their non-combustible strategy, with little to show other than how not to transform a business. On the other end of the spectrum, Philip Morris, until recently out of theStriving to compound knowledge. Long-time fan of Warren and Charlie. Always invert. "To finish first, you must first finish". Investing own and family funds for +20 years. Senior finance roles at public and private corporations for most of that time.Analy ...

Core Viewpoint - Altria Group, Inc. is set to report its first-quarter 2025 earnings, with expectations of a slight revenue decline but earnings growth compared to the previous year [1][2]. Revenue and Earnings Estimates - The Zacks Consensus Estimate for first-quarter revenues is $4.6 billion, reflecting a 1.7% decline year-over-year [2]. - The earnings estimate has decreased by 2 cents to $1.17 per share, indicating a 1.7% growth from the same quarter last year [2]. - Altria has a trailing four-quarter average negative earnings surprise of 0.2%, but in the last quarter, it exceeded the consensus estimate by 1.6% [2]. Earnings Prediction Model - The current model does not predict a definitive earnings beat for Altria, as it has an Earnings ESP of -2.69% and a Zacks Rank of 3 (Hold) [3][4]. Strategic Focus - Altria's strategic transformation towards smoke-free products is a key focus, with efforts to expand its portfolio of reduced-risk offerings like NJOY e-vapor products and on! nicotine pouches [5]. - The "Optimize & Accelerate" initiative aims to modernize operations and enhance progress towards a smoke-free vision [5]. Performance Influences - Strength in smoke-free products is expected to positively impact first-quarter performance, although significant investments in R&D and marketing may affect profitability [6]. - The Smokeable Products segment remains crucial, contributing 88.1% of total revenues in Q4 2024, but faces challenges from declining cigarette volumes due to macroeconomic factors [7]. Valuation Analysis - Altria shares are trading at a forward 12-month price-to-earnings ratio of 10.99, below the Zacks Tobacco industry average of 14.86, indicating attractive valuation for investors [8]. - Compared to competitors, Altria's valuation is lower than Philip Morris International (P/E of 22.74) and Turning Point Brands (P/E of 16.72), while British American Tobacco trades at a P/E of 9.23 [10]. Stock Performance - Over the past three months, Altria stock has returned 9.8%, underperforming the industry gain of 20.8% but outperforming the S&P 500's decline of 11% [11]. - Altria has shown relative strength compared to peers like Turning Point Brands and British American Tobacco, but Philip Morris has outperformed with a 30.4% gain [11]. Investment Outlook - Altria's attractive valuation, defensive sector positioning, and stable performance make it a compelling choice for long-term investors in the tobacco sector [13].

Core Viewpoint - Growth investors are attracted to stocks with above-average financial growth, but identifying such stocks can be challenging due to associated risks and volatility [1] Group 1: Company Overview - Philip Morris (PM) is highlighted as a recommended stock with a favorable Growth Score and a top Zacks Rank [2] - The company has a historical EPS growth rate of 4%, but projected EPS growth for this year is expected to be 10.7%, surpassing the industry average of 10.6% [5] Group 2: Financial Metrics - Earnings growth is crucial for attracting investor attention, with double-digit growth being particularly favorable [4] - Philip Morris has a year-over-year cash flow growth of 5.5%, significantly higher than the industry average of 0.3% [6] - The company's annualized cash flow growth rate over the past 3-5 years is 5.9%, compared to the industry average of 4.6% [7] Group 3: Earnings Estimates - Positive trends in earnings estimate revisions correlate strongly with near-term stock price movements [8] - The current-year earnings estimates for Philip Morris have increased by 4.6% over the past month [9] Group 4: Investment Potential - Philip Morris has earned a Growth Score of B and a Zacks Rank 2 due to positive earnings estimate revisions, indicating potential for outperformance and suitability for growth investors [11]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported double-digit increases in organic net revenue, operating income, and adjusted diluted EPS in both constant currency and dollar terms [6][11][12] - Organic net revenue growth was plus 10.2%, reaching $9.3 billion, with volume growth of plus 3.9% [12][14] - Adjusted diluted EPS grew by plus 17.3% in constant currency and by plus 12.7% in dollar terms to $1.69, despite a $0.07 unfavorable currency variance [14][59] Business Line Data and Key Metrics Changes - The smoke-free business saw shipment volumes increase by plus 14.4% year-on-year, with organic net revenue growth of plus 20% and organic gross profit growth of plus 33% [6][16] - IQOS delivered close to plus 10% HTU-adjusted IMS growth, with strong performance in Japan and Europe [7][11] - ZYN shipments increased by plus 53% to reach 202 million cans, exceeding initial expectations [8][43] Market Data and Key Metrics Changes - The international nicotine pouch can volumes grew by plus 53%, or plus 182% excluding the Nordics, indicating strong global demand [9][50] - In Europe, total shipments of IQOS advanced by plus 17.5% in Q1, with significant growth in markets like Spain, Germany, and Bulgaria [30][32] - The cigarette industry declined by 1.3% in Q1, with growth in markets where smoke-free products are not present, such as Turkey and India [54] Company Strategy and Development Direction - The company continues to deploy a multi-category strategy across markets, with smoke-free products now accounting for 44% of total gross profit [6][7] - The focus remains on expanding the smoke-free portfolio, with significant investments in brand building and product innovation [29][30] - The company aims to achieve double-digit growth for the rest of the year and has raised its shipment forecast for ZYN to 800 million to 840 million cans per year [12][58] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving another year of super growth despite uncertainties in the global economic outlook [11][59] - The company anticipates continued strong momentum from its smoke-free business and expects to mitigate potential supply chain challenges [57][65] - Management highlighted the importance of maintaining a progressive dividend policy while focusing on sustainable growth [65][66] Other Important Information - The company delivered over $180 million in gross cost savings in Q1, placing it on track to achieve a $2 billion target over 2024-2026 [27] - The company is committed to investing in U.S. manufacturing, with significant job creation expected as a result [49] Q&A Session Summary Question: ZYN out-of-stock issues and inventory rebuilding timeline - Management acknowledged ongoing out-of-stock issues and indicated that replenishment would occur gradually, with normalization expected by Q3 2025 [68][73] Question: Drivers of continued margin expansion - Management highlighted that smoke-free products are driving margin expansion, with a significant organic gross margin increase in Q1 [75][78] Question: Guidance outlook for the second half of the year - Management indicated that traditional differences between H1 and H2 could affect growth rates, but overall strong momentum is expected [85][89] Question: Unconstrained growth for ZYN - Management noted that while they cannot provide precise estimates for unconstrained demand, they expect consumer offtake to accelerate as supply constraints are lifted [100][102] Question: Net interest cost guidance for the year - Management did not provide specific guidance for net interest costs but indicated a positive start to the year [116][119]